Research graph
References from Lower doses of carvedilol in Japanese heart failure patients with reduced ejection fraction could show the potential to be non-inferior to higher doses in US patients: An international collaborative observational study. Local targets link to admitted publications; unresolved targets remain external evidence.
Changes in mortality in top 10 causes of death from 2011 to 2018
10.1007/s11606-020-06070-z · 2021 · External reference
Unresolved reference
External reference
2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines
2022 · External reference
JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure
10.1253/circj.cj-21-0431 · 2021 · External reference
The cardiac insufficiency bisoprolol study II
10.1016/s0140-6736(05)74356-7 · 1999 · External reference
A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). CIBIS investigators and committees
10.1161/01.cir.90.4.1765 · 1994 · External reference
Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL randomised intervention trial in congestive heart failure (MERIT-HF)
10.1016/s0140-6736(99)04440-2 · 1999 · External reference
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): Randomised controlled trial
10.1016/s0140-6736(03)13800-7 · 2003 · External reference
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA investigators
10.1161/01.cir.94.11.2807 · 1996 · External reference
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group
10.1056/nejm199605233342101 · 1996 · External reference
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study
10.1161/01.cir.0000035653.72855.bf · 2002 · External reference
Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The multicenter carvedilol heart failure dose assessment (MUCHA) trial
10.1016/j.ahj.2003.07.023 · 2004 · External reference
Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study
10.1016/j.ijcard.2012.11.051 · 2013 · External reference
Investigators. High dose β-blocker therapy triggers additional reverse remodeling in patients with idiopathic non-ischemic cardiomyopathy: A lesson from a preliminary trial including the significance of left ventricular diameter and BNP change for reverse remodeling
10.1536/ihj.16-157 · 2016 · External reference
Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker
10.1007/bf00544245 · 1987 · External reference
Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology
10.1002/prp2.496 · 2019 · External reference
Unresolved reference
External reference
CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects
10.1016/j.clpt.2003.10.004 · 2004 · External reference
Beta-blockers and 1-year postdischarge mortality for heart failure and reduced ejection fraction and slow discharge heart rate
10.1161/jaha.118.011121 · 2019 · External reference
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics
10.2217/pgs.11.20 · 2011 · External reference
Unresolved reference
External reference
Influence of global region on outcomes in heart failure beta-blocker trials
10.1016/j.jacc.2011.03.057 · 2011 · External reference
Heart failure clinical trials in East and Southeast Asia: Understanding the importance and defining the next steps
10.1016/j.jchf.2016.01.013 · 2016 · External reference
Asian" phenotype underestimates the genetic diversity of Asia yet overstates its impact on variability in drug disposition and pharmacodynamics
10.1002/cpt.1329 · 2019 · External reference
